依鲁替尼在复发/难治性边缘区淋巴瘤中的持久缓解:长期随访与生物标志物分析
PCYC-1121 2期研究最终分析纳入63例既往接受利妥昔单抗或利妥昔单抗为基础化疗免疫治疗的复发/难治性边缘区淋巴瘤患者,依鲁替尼560 mg/d单药治疗中位随访33.1个月,总缓解率58%,中位缓解持续时间27.6个月,中位无进展生存期15.7个月,中位总生存期未达到;安全性与此前报道一致,探索性生物标志物分析显示NF-κB通路基因突变与结局相关。
要点
- 依鲁替尼560 mg/d在复发/难治性边缘区淋巴瘤中总缓解率58%,中位缓解持续时间27.6个月。
- 既往仅利妥昔单抗者总缓解率81%、中位无进展生存期30.4个月,优于既往利妥昔单抗联合化疗者。
- 最常见≥3级不良事件为贫血(16%),长期安全性与此前报道一致。
核心结论
- PCYC-1121最终分析显示依鲁替尼在复发/难治性边缘区淋巴瘤中具有长期安全性和疗效,无论既往治疗或边缘区淋巴瘤亚型。
研究设计与样本
- 2期PCYC-1121研究纳入63例既往接受利妥昔单抗或利妥昔单抗为基础化疗免疫治疗的复发/难治性边缘区淋巴瘤患者,给予依鲁替尼560 mg/d单药治疗。
- 最终分析中位随访33.1个月(范围1.4-44.6个月),依鲁替尼治疗最长45个月。
主要发现
- 总缓解率58%;中位缓解持续时间27.6个月(95%CI 12.1至不可估计);中位无进展生存期15.7个月(95%CI 12.2-30.4);中位总生存期未达到(95%CI 不可估计至不可估计)。
- 既往利妥昔单抗治疗者总缓解率81%、中位缓解持续时间未达到(95%CI 12.2至不可估计)、中位无进展生存期30.4个月(95%CI 22.1至不可估计)、中位总生存期未达到(95%CI 30.3至不可估计)。
- 既往利妥昔单抗联合化疗免疫治疗者总缓解率51%、中位缓解持续时间12.4个月(95%CI 2.8至不可估计)、中位无进展生存期13.8个月(95%CI 8.3-22.5)、中位总生存期未达到(95%CI 不可估计至不可估计)。
- 结外、结内和脾边缘区淋巴瘤亚型的总缓解率分别为63%、47%和62%。
- 最常见≥3级不良事件为贫血(16%);探索性生物标志物分析显示NF-κB通路基因突变与结局相关。
临床怎么用
- 对于既往接受过利妥昔单抗或利妥昔单抗为基础化疗免疫治疗的复发/难治性边缘区淋巴瘤患者,可考虑依鲁替尼560 mg/d单药治疗。
- 既往仅接受利妥昔单抗的患者可能从依鲁替尼治疗中获得更高的缓解率和更长的无进展生存期。
- 治疗期间应关注贫血等≥3级不良事件,长期用药安全性与此前报道一致。
局限性
- 本研究为单臂2期研究,样本量63例,未设对照组,结果需在更大规模研究中验证。
- 生物标志物分析为探索性,NF-κB通路基因突变与结局的相关性需进一步确认。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Advanced marginal zone lymphoma (MZL) is an incurable B-cell malignancy dependent on B-cell receptor signaling. The phase 2 PCYC-1121 study demonstrated the safety and efficacy of single-agent ibrutinib 560 mg/d in 63 patients with relapsed/refractory MZL treated with prior rituximab (RTX) or rituximab-based chemoimmunotherapy (RTX-CIT). We report the final analysis of PCYC-1121 with median follow-up of 33.1 months (range: 1.4-44.6). Overall response rate (ORR) was 58%; median duration of response (DOR) was 27.6 months (95% confidence interval [CI]: 12.1 to not estimable [NE]); median progression-free survival (PFS) was 15.7 months (95% CI: 12.2-30.4); and median overall survival (OS) was not reached (95% CI: NE to NE). Patients with prior RTX treatment had better outcomes (ORR: 81%; median DOR: not reached [95% CI: 12.2 to NE]; median PFS: 30.4 months [95% CI: 22.1 to NE]; median OS: not reached [95% CI: 30.3 to NE]) vs those with prior RTX-CIT treatment (ORR: 51%; DOR: 12.4 months [95% CI: 2.8 to NE]; PFS: 13.8 months [95% CI: 8.3-22.5]; OS: not reached [95% CI: NE to NE]). ORRs were 63%, 47%, and 62% for extranodal, nodal, and splenic subtypes, respectively. With up to 45 months of ibrutinib treatment, the safety profile remained consistent with prior reports. The most common grade ≥3 event was anemia (16%). Exploratory biomarker analysis showed NF-κB pathway gene mutations correlated with outcomes. Final analysis of PCYC-1121 demonstrated long-term safety and efficacy of ibrutinib in patients with relapsed/refractory MZL, regardless of prior treatment or MZL subtype. This trial was registered at www.clinicaltrials.gov as #NCT01980628.
引用
- Noy A, de Vos S, Coleman M, et al. Durable ibrutinib responses in relapsed/refractory marginal zone lymphoma: long-term follow-up and biomarker analysis. Blood Adv. 2020. PMID: 33227125. doi:10.1182/bloodadvances.2020003121
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。